Stefan Geschwindner (AstraZeneca) presents Salipro collaboration at the 6th NovAliX Conference3/22/2019
Presentation from Stefan Geschwindner (AstraZeneca) at the 6th edition of NovAliX conference, including data on our collaboration on challenging membrane protein targets with Salipro® and SPR.
 Salipro Biotech signs multi-target agreement with an additional global pharma company. Salipro Biotech will apply its expertise and its unique membrane protein technology to advance programs on challenging targets selected by the pharmaceutical partner.
Out now: Salipro® goes Biacore™ systems - See the results of our collaboration with GE Healthcare on antibody binding to membrane proteins, detergent-free, in our Application Note (link)
Salipro Biotech receives “Groundbreaking Idea Grant” from the Swedish Innovation Agency for the development of therapeutic antibodies.
Salipro Biotech receives notice of allowance from U.S. Patent and Trademark Office relevant to its Salipro® technology for the stabilisation of drug targets
Meet us at the GE Healthcare DiPIA meeting in Boston (June 17-20), presenting a poster with the results of our collaboration with GE Healthcare.
Salipro® for functional studies of a GPCR with NMR. Half-life of GPCR in Salipro® extended from 1.5 to 30 days. Check out the latest paper on our technology by Nietlispach et al: http://pubs.acs.org/doi/10.1021/jacs.7b06730
CEO Jens Frauenfeld invited speaker at the 10th Annual Proteins & Antibodies Congress in London.
Salipro Biotech is recipient of the Ingemar Croon Award 2017 (2 MSEK).
|
© SALIPRO BIOTECH AB - TEKNIKRINGEN 38A - 114 28 STOCKHOLM - SWEDEN